CRISPR trials yield encouraging data in blood disordersData on the first two patients to be treated with a CRISPR-based drug for the blood disorders beta Share XCRISPR trials yield encouraging data in blood disordershttps://pharmaphorum.com/news/crispr-trials-yield-encouraging-data-in-blood-disorders/
Vertex gets early okay for cystic fibrosis triple Trikafta in USVertex Pharma has claimed an ultra-fast approval in the US for Trikafta, its three-drug combination that provides a Share XVertex gets early okay for cystic fibrosis triple Trikafta in UShttps://pharmaphorum.com/news/vertex-gets-early-okay-for-cystic-fibrosis-triple-trikafta-in-us/
Labour government would use compulsory licensing for expensive drugsA Labour government would force pharma companies to make essential drugs available that are affordable by the NHS, Share XLabour government would use compulsory licensing for expensive drugshttps://pharmaphorum.com/news/labour-government-would-use-compulsory-licensing-for-expensive-drugs/
Vertex’ chief Leiden to step down, with CMO named successorJeffrey Leiden is leaving Vertex Pharma after seven years as president and CEO, to be replaced by chief Share XVertex’ chief Leiden to step down, with CMO named successorhttps://pharmaphorum.com/news/vertex-chief-leiden-to-step-down-with-cmo-named-successor/
Vertex presses go on its cystic fibrosis triple filingVertex has launched the next phase of its plan for the cystic fibrosis market, filing for approval of Share XVertex presses go on its cystic fibrosis triple filinghttps://pharmaphorum.com/news/vertex-presses-go-on-its-cystic-fibrosis-triple-filing/
R&D roundup: the ups and downs of CRISPR and Alzheimer’sWhile the controversy surrounding Vertex Pharma’s cystic fibrosis drug in the UK grows more intense, the US firm Share XR&D roundup: the ups and downs of CRISPR and Alzheimer’shttps://pharmaphorum.com/r-d/views-analysis-r-d/rd-roundup-the-ups-and-downs-of-crispr-and-alzheimers/
